Table 2.
Reference (Authors / year) | Prior therapy | Rituximab dose (mg/m2) | Cycles | Other agents | Evaluable patients | ORR (CR) |
---|---|---|---|---|---|---|
Byrd et al., 2001 | Yes | 375 q4wks | 6 | Flu | 51 | 90% (47%) |
Schulz et al., 2002 | Yes | 375 q4wks | 4 | Flu | 31 | 87% (32%) |
Wierda et al., 2005 | Yes | 500 q4wks | 6 | Flu/Cy | 177 | 73% (25%) |
Keating et al, 2005 | No | 500 q4wks | 6 | Flu/Cy | 300 | 94% (72%) |
Wierda et al, 2006 | Yes | 500 q4wks | 6 | Flu/Cy/A | 78 | 65% (24%) |
Kay et al, 2007 | No | 375 q3wks | 6 | Pent/Cy | 64 | 91% (41%) |
Abbreviations: Fludarabine (Flu), Cyclophosphamide (Cy), Alemtuzumab (A), Pentostatin (Pent)